Table 5.
Summary of the study results per disease. Statistically significant differences in adherence outcomes are presented and considered.
| Disease | Comparison of Adherence Outcome between FDCT and MPT; Number of Studies with Certain Result Is Given in Parenthesis | References |
|---|---|---|
| CVD (n = 11) |
FDCT > MPT (n = 9) | [35,45,48,49,52,59,60,62,63] |
| FDCT = MPT (n = 1) | [58] | |
| Inconclusive * (n = 1) | [61] | |
| HT (n = 31) |
FDCT > MPT (n = 28) | [5,33,38,39,40,41,42,46,53,55,56,64,65,66,67,68,69,70,71,72,73,74,77,78,79,81,82,83] |
| FDCT = MPT (n = 2) | [75,76] | |
| Inconclusive * (n = 1) | [80] | |
| DMII (n = 10) |
FDCT > MPT (n = 9) | [31,32,36,44,51,54,84,85,86] |
| Inconclusive * (n = 1) | [43] | |
| HIV (n = 14) | FDCT > MPT (n = 10) | [30,37,57,87,88,89,91,92,93,94] |
| FDCT = MPT (n = 3) | [34,50,90] | |
| Inconclusive * (n = 1) | [47] | |
| Other (n = 1) | FDCT = MPT (n = 1) | [95] |
* Several outcomes were observed (FDCT < MPT or FDCT > MPT or FDCT = MPT). See Table A2 (Appendix B) and Table A3 (Appendix C) for additional information. FDCT, fixed-dose combination therapy; MPT, multipill therapy; CVD, cardiovascular disease; DMII, diabetes mellitus type 2; LUTS/BHP, Lower urinary tract symptoms associated with benign prostatic hyperplasia; HIV, human immunodeficiency virus.